Retatrutide is designed to activate GLP-1, GIP, and glucagon receptors (triple agonist), and researchers study how that impacts metabolic endpoints in clinical trials
In clinical trials, Mounjaros active ingredient, tirzepatide, helped people lose 22.5% on average, while semaglutide (Ozempic and Wegovys active ingredient) helped people lose around 21% of their starting weight
doi:10.3390/antiox11010050 27
Eli Lilly, if Im reading this right is suggesting that somewhere between 4-6% of patients in the retatrutide arms stopped taking the drug due to excessive weight loss
The medication's multi-target approach suggests it may possess a tolerable safety profile similar to current weight loss prescriptions once fully approved
2 3 days from your local domestic warehouse